1. Home
  2. LRE vs NCEL Comparison

LRE vs NCEL Comparison

Compare LRE & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

HOLD

Current Price

$1.10

Market Cap

17.9M

Sector

N/A

ML Signal

HOLD

Logo NewcelX Ltd. Ordinary Shares

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$2.95

Market Cap

19.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRE
NCEL
Founded
2001
2008
Country
Japan
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
19.4M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
LRE
NCEL
Price
$1.10
$2.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 12.8K
5.7K
Earning Date
07-30-2015
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.16
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$1.83
52 Week High
$1.86
$5.12

Technical Indicators

Market Signals
Indicator
LRE
NCEL
Relative Strength Index (RSI) 34.51 40.84
Support Level N/A $2.72
Resistance Level $1.34 $3.16
Average True Range (ATR) 0.05 0.22
MACD -0.01 -0.03
Stochastic Oscillator 35.81 32.62

Price Performance

Historical Comparison
LRE
NCEL

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: